CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Alemtuzumab +1 moredrug
Likely dose
Alemtuzumab 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00436904
NCT00436904Phase 2Completed
CompareCT.gov

Antibody Therapy With Alemtuzumab and Rituximab for Initial Treatment of High Risk Chronic Lymphocytic Leukemia

Mayo Clinic·interventional·Posted Feb 19, 2007·Updated Dec 1, 2011

In Brief

A Phase 2 clinical trial evaluating Alemtuzumab and Rituximab for Leukemia. Completed, enrolled 30 participants across 1 site.

Detailed Summary

RATIONALE: Monoclonal antibodies, such as alemtuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving alemtuzumab together with rituximab may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well giving alemtuzumab together with rituximab works in treating patients with high-risk, early-stage chronic lymphocytic leukemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 19, 2007
Enrollment StartDec 1, 2004
Primary CompletionJul 1, 2008
Study CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 19.4 years ago

Interventions

Alemtuzumabdrug

30 mg Monday, Wednesday, and Friday x 5 weeks

Rituximabdrug

375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)